Literature DB >> 3950635

Changes in the human visual evoked potential caused by the anticholinergic agent hyoscine hydrobromide: comparison with results in Alzheimer's disease.

A A Bajalan, C E Wright, V J van der Vliet.   

Abstract

The anticholinergic drug hyoscine hydrobromide produced a slowing of the P2 and N3 components of the flash visual evoked potential (VEP) in young normals but did not affect the pattern reversal VEP. These results, which are similar to those found in Alzheimer's disease, could be explained by an underlying defect of the cholinergic system.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3950635      PMCID： PMC1028683          DOI： 10.1136/jnnp.49.2.175

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  21 in total

1.  Central nervous system effects of hyoscine in man.

Authors:  A M OSTFELD; A ARUGUETE
Journal:  J Pharmacol Exp Ther       Date:  1962-07       Impact factor: 4.030

2.  Human memory and the cholinergic system. A relationship to aging?

Authors:  D A Drachman; J Leavitt
Journal:  Arch Neurol       Date:  1974-02

3.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

4.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

5.  Visual evoked response in senile and presenile dementia.

Authors:  S L Visser; F C Stam; W van Tilburg; W den Velde; J L Blom; W de Rijke
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1976-04

6.  The ascending cholinergic reticular system: neocortical, olfactory and subcortical projections.

Authors:  C C Shute; P R Lewis
Journal:  Brain       Date:  1967-09       Impact factor: 13.501

7.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

Authors:  D M Bowen; C B Smith; P White; A N Davison
Journal:  Brain       Date:  1976-09       Impact factor: 13.501

8.  Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains.

Authors:  P Davies; A H Verth
Journal:  Brain Res       Date:  1977-12-16       Impact factor: 3.252

9.  Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.

Authors:  E K Perry; P H Gibson; G Blessed; R H Perry; B E Tomlinson
Journal:  J Neurol Sci       Date:  1977-11       Impact factor: 3.181

10.  An analysis of the learning deficit following hyoscine administration to man.

Authors:  T J Crow; I G Grove-White
Journal:  Br J Pharmacol       Date:  1973-10       Impact factor: 8.739
View more
  5 in total

1.  Comparison of the effects of Alzheimer's disease, normal aging and scopolamine on human transient visual evoked potentials.

Authors:  A T Smith; F Early; G H Jones
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Visual evoked potentials to flash and pattern reversal stimulation after administration of systemic or topical scopolamine.

Authors:  G F Harding; R Daniels; S Panchal; N Drasdo; S J Anderson
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

3.  Cholinesterase inhibitors affect brain potentials in amnestic mild cognitive impairment.

Authors:  Rie Irimajiri; Henry J Michalewski; Edward J Golob; Arnold Starr
Journal:  Brain Res       Date:  2007-02-02       Impact factor: 3.252

4.  The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task.

Authors:  P M Grasby; C D Frith; E Paulesu; K J Friston; R S Frackowiak; R J Dolan
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

5.  Comparison of visual evoked potentials and retinal nerve fiber layer thickness in Alzheimer's disease.

Authors:  Robert Kromer; Nermin Serbecic; Lucrezia Hausner; Lutz Froelich; Sven C Beutelspacher
Journal:  Front Neurol       Date:  2013-12-16       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.